Medtronic plc (NYSE: MDT) is a Dublin-headquartered medical technology company whose devices span cardiac rhythm management, surgical robotics, diabetes, and spine care. After a volatile 2026 that saw the shares slide toward $79 in early July before recovering to roughly $94 by late October, investors are weighing whether the stock can climb to a $104 central price target.
Across approximately 30 current analyst price targets, individual objectives cluster in a wide band from roughly $83 on the cautious end to about $121 at the top. The arithmetic mean works out to approximately $104, which is the central target used here. Independent aggregators broadly corroborate this figure: S&P Global data places the average near $104–$105, while MarketBeat's 28-analyst average sits just under $103.
The dispersion matters more than the midpoint. Bullish firms include RBC Capital ($118, Buy), Mizuho ($115, Outperform), Needham ($114, Buy), Bernstein ($112, Outperform), and Leerink Partners ($111, Outperform). More cautious voices such as Piper Sandler ($85, Hold), Goldman Sachs (low $80s, Hold), and Deutsche Bank ($92, Hold) argue that much of the growth story is already reflected in the multiple. Barclays initiated coverage with an Equal Weight rating and a $95 target in early October, framing a neutral stance.
With the shares near $94, the move to a $104 target requires roughly 11% upside — a modest but not insignificant climb. The path runs through Medtronic's fiscal 2027 first quarter (ended July 31, 2026), which delivered revenue of $9.76 billion and net income of $1.47 billion, up from $8.58 billion and $1.04 billion a year earlier. Reported organic revenue growth of 13.7% was flattered by an extra fiscal week contributing about $570 million, but management still raised full-year organic growth guidance to 7.25%–7.75%.
Cardiac Ablation Solutions was the standout, with revenue up 88%, while cardiac rhythm management, pelvic health, and diabetes each grew about 15%. This broadening beyond a single growth engine is central to the bull case for a higher valuation, though analysts disagree on whether it justifies a re-rating.
The shares have recovered from a July 2026 low near $79 to the mid-$90s, but the $100 round-number level remains an important psychological hurdle sitting between the current price and the $104 target. Many analyst targets cluster in the $100–$118 zone, suggesting that a sustained move above $100 could be the structural step needed before the central target comes into view. A failure to hold recent gains could see the stock retest support near its earlier 2026 lows.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary in their modeling windows. Key items ahead include Medtronic's next quarterly earnings and any update to fiscal 2027 guidance, additional analyst target revisions, commentary on cardiac ablation market share, the integration of the Cornerstone Robotics investment, and broader economic data affecting hospital spending. Management's December Investor Day could also clarify the longer-term growth trajectory.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a stock like Medtronic, where the analyst debate is finely balanced, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review. Consider exploring these signals as a complement to fundamental research.
The $104 central target reflects the average of roughly 30 analyst objectives spanning $83 to $121, and it implies about 11% upside from a price near $94. The bull case rests on a broadening, beat-and-raise growth story and a strengthening pipeline, while the bear case centers on valuation, competitive pressure in cardiac ablation, and execution risk. The wide target range signals genuine disagreement about how much of the recovery is already priced in. Whether Medtronic reaches $104 will depend on sustained organic growth, guidance durability, and whether investors award the stock a higher multiple — none of which is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
| Ticker / NAME | Correlation To MDT | 1D Price Change % |
|---|---|---|
| MDT | 100% | -0.61% |
| Health Services category (239 stocks) | 12% Poorly correlated | -1.79% |
| Medical/Nursing Services category (138 stocks) | 10% Poorly correlated | -1.87% |